Clinical Research and Guidelines Videos

In this video, Prof. Christopher Cannon explored the future of ASCVD and lipidology. He talks about the recent expanded indication for evlocumab and new indication for inclisiran, upcoming guidelines on LDL management, the development of oral PCSK9 inhibitors, CETP inhibitors, upcoming trials on Lp(a), and strategies for managing triglycerides.

Prof. Christopher Cannon

First published: October 6, 2025  

Check out our latest animated video to learn more about the one-year follow-up of the SANTORINI study.

First published: March 13, 2025  

In this video, Prof. Maciej Banach discusses the 2024 recommendations on the optimal use of LLT in established ASCVD and following ACS.

First published: March 4, 2025  

In this video, Prof Stephen Nicholls discusses the future of ASCVD and Lipidology in 2025.

First published: February 24, 2025  

Welcome to our latest video! This video explores the emerging role of inclisiran, a small interfering RNA (siRNA) therapeutic that targets PCSK9, in the management of atherosclerotic cardiovascular disease. The summary delves into the mechanism of actions of inclisiran, its safety profile, results from clinical trials and the latest data presented at the ESC congress.

First published: January 13, 2025  

In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the World Heart Foundation’s Cholesterol Roadmap (2022) for the management and prevention of atherosclerotic cardiovascular disease (ASCVD). He discusses various approaches for ASCVD prevention, emphasizes regional differences in adherence to ASCVD treatment guidelines, and highlights barriers to effective risk management. This roadmap offers a scientifically sound foundation for policymakers to implement changes aimed at reducing the burden of ASCVD.

Prof. Christopher Cannon

First published: August 1, 2024  

In this video, we summarize the results from the SANTORINI trial which documents the effectiveness of current treatment practice in managing LDL-C levels for patients in the higher CV risk categories in and how care may be improved.

First published: July 12, 2023  

A Peer-to-Peer Discussion

In this specially compiled video, Dr. Carl Orringer, a past president of the National Lipid Association (NLA), shares his views on the recently published NLA Scientific Statement on Lipid Measurements in the Management of Cardiovascular Diseases in a conversation with our Editorial Panel Member, Prof. Lale Tokgözoğlu. The experts discuss the importance of these lipoprotein measurements to clinicians and other healthcare professionals providing treatment and the importance of shared decision making (SDM) in improving patient care.

Prof. Lale Tokgözoğlu, Dr. Carl Orringer

First published: October 21, 2021